0000000001318171

AUTHOR

Basem Qeshta

showing 5 related works from this author

1-(Pyridin-4-yl)-3-(2,4,6-trichlorophenyl)benz[4,5]imidazo[1,2-d][1,2,4]triazin-4(3H)-one

2016

In the title compound, C20H10Cl3N5O, the 13-membered ring system makes dihedral angles of 78.64 (9)° with the trichlorophenyl ring and 62.60 (10)° with the pyridine ring. The crystal packing is dominated by π–π interactions between the 13-membered ring systems [centroid–centroid distance = 3.6655 (11)°].

0301 basic medicinepyridinecrystal structure246-trichlorophenylStereochemistryCentroidGeneral MedicineCrystal structureDihedral angleRing (chemistry)124-triazinoneCrystalbenzoimidazole03 medical and health sciencesCrystallographychemistry.chemical_compound030104 developmental biology0302 clinical medicinechemistry030220 oncology & carcinogenesisPyridinelcsh:QD901-999lcsh:CrystallographyIUCrData
researchProduct

Crystal structures of pure 3-(4-bromo-2-chloro­phen­yl)-1-(pyridin-4-yl)benzo[4,5]imidazo[1,2-d][1,2,4]triazin-4(3H)-one and contaminated with 3-(4-b…

2017

The side product of the cyclo­condensation reaction between ethyl benzimidazole-2-carboxyl­ate and the nitrile imine of the corresponding hydrazonyl chloride, C20H11BrClN5O, crystallized in two crystal forms. Form (1) is a co-crystal of the target compound (without any chlorine substituent) and a side product containing a Cl atom in position 2 of the bromo­phenyl group, C20H12BrN5O·0.143C20H11BrClN5O. (2) contains the pure side product. The slightly different conformation of the ring systems leads to a different packing of (1) and (2), but both crystal structures are dominated by p-p inter­actions.

benzoimidazolepyridine540 Chemistry and allied sciencescrystal structureCrystallographyQD901-999540 Chemie4-bromo-2-chlorophenyl4-bromo-2-chloro­phen­ylbenzo­imidazole124-triazinoneResearch CommunicationsActa Crystallographica Section E: Crystallographic Communications
researchProduct

3-(2,4-Difluorophenyl)-1-(pyridin-4-yl)benzo[4,5]imidazo[1,2-d][1,2,4]triazin-4(3H)-one

2016

In the title compound, C20H11F2N5O, the central 13-membered ring system (r.m.s. deviation = 0.028 Å) makes a dihedral angle of 53.13 (7)° with the difluorophenyl ring and 79.98 (7)° with the pyridine ring. The crystal packing features aromatic π–π interactions between the 13-membered rings [shortest distance between ring centroids = 3.5682 (8) Å].

pyridinecrystal structureShortest distanceStereochemistryChemistryGeneral MedicineCrystal structuredifluorophenylDihedral angle010402 general chemistry010403 inorganic & nuclear chemistryRing (chemistry)01 natural sciences124-triazinone0104 chemical sciencesbenzoimidazoleCrystalCrystallographychemistry.chemical_compoundPyridinelcsh:QD901-999lcsh:CrystallographyIUCrData
researchProduct

Design, Synthesis and Biological Evaluation of Novel Pyrazolo[1,2,4]triazolopyrimidine Derivatives as Potential Anticancer Agents

2021

Three novel pyrazolo-[4,3-e][1,2,4]triazolopyrimidine derivatives (1, 2, and 3) were designed, synthesized, and evaluated for their in vitro biological activity. All three compounds exhibited different levels of cytotoxicity against cervical and breast cancer cell lines. However, compound 1 showed the best antiproliferative activity against all tested tumor cell lines, including HCC1937 and HeLa cells, which express high levels of wild-type epidermal growth factor receptor (EGFR). Western blot analyses demonstrated that compound 1 inhibited the activation of EGFR, protein kinase B (Akt), and extracellular signal-regulated kinase (Erk)1/2 in breast and cervical cancer cells at concentrations…

cervical cancercrystal X-ray analysisPharmaceutical ScienceAntineoplastic AgentsArticleAnalytical ChemistryHeLa03 medical and health sciencesbreast cancerQD241-4410302 clinical medicineDrug DiscoveryHumansEpidermal growth factor receptorPhysical and Theoretical Chemistrypyrazolo[124]triazolopyrimidineCytotoxicityProtein Kinase InhibitorsProtein kinase BCell Proliferation030304 developmental biologyMitogen-Activated Protein Kinase 1pyrazolo[124]triazolopyrimidine; EGF-receptor inhibitor; breast cancer; cervical cancer; molecular docking; crystal X-ray analysis0303 health sciencesBinding SitesMitogen-Activated Protein Kinase 3biologyChemistryKinaseOrganic ChemistryBiological activitymolecular dockingTriazolesbiology.organism_classificationMolecular biologyIn vitroErbB ReceptorsMolecular Docking SimulationPyrimidinesChemistry (miscellaneous)Docking (molecular)030220 oncology & carcinogenesisbiology.proteinMolecular MedicineProto-Oncogene Proteins c-aktEGF-receptor inhibitorHeLa CellsProtein BindingMolecules
researchProduct

CCDC 2042388: Experimental Crystal Structure Determination

2021

Related Article: Saeb Aliwaini, Bassam Abu Thaher, Ihab Al-Masri, Nabil Shurrab, Said El-Kurdi, Dieter Schollmeyer, Basem Qeshta, Mariam Ghunaim, Ren�� Csuk, Stefan Laufer, Lars Kaiser, Hans-Peter Deigner|2021|Molecules|26|4065|doi:10.3390/molecules26134065

Space GroupCrystallographyCrystal System4-[7-(4-bromophenyl)-7H-pyrazolo[43-e][124]triazolo[15-c]pyrimidin-9-yl]pyridin-1-ium trifluoroacetate trifluoroacetic acid unknown solvateCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct